Page 33 - P4403.14-V111 December OTC Magazine 2025 NI_Neat

GASTRO 33

ARE YOUR Save

PATIENTS 19% Off

TREATING THE Trade
CAUSE OF THEIR

FREQUENT

HEARTBURN?

FREQUENT HEARTBURN
OCCURS MORE THAN
ONCE A WEEK

NO OTHER HEARTBURN
REMEDY LASTS LONGER
WITHOUT PRESCRIPTION 1,2
Esomeprazole
Heartburn is caused by stomach acid rising up (reflux)
into the oesophagus. Frequent heartburn makes the
oesophagus sensitive to acid so it doesn’t take much to
trigger the pain.

NICE guidelines recommend PPIs as first line treatment
for frequent heartburn. Nexium Control treats the cause
3
and symptoms of frequent heartburn by reducing the
production of stomach acid.

DISCOVER THE SCIENCE
OF NEXIUM CONTROL

1. Lind T et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol
Ther 2000; 14: 861-7 2. Rohss K et al. Esomeprazole 20mg provides more effective instragastric acid control than maintenance-dose rabeprazole, lansoprazole or
pantaprazole in healthy volunteers. Clin Drug Invest 2004; 24(1): 1-7. 3. NICE guidelines CG184 Sept 2014.
Nexium Control 20 mg gastro-resistant tablets. Active ingredient: Esomeprazole Indications: The short term treatment of reflux symptoms (e.g. heartburn and
acid regurgitation) in adults. Legal category: P: 28s tablets. PL holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K.
Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at:
https://www.medicines.org.uk/emc/product/14465/smpc
Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-NEX-23-00012.

Trade POR
Buying
Product Size Price/Single RRP Offer % % Pip Code
NEXIUM
NEXIUM CONTROL CAPS 20MG 14 £6.70 £13.99 19% 43% 4049888
NEXIUM CONTROL TABS 20MG 14 £6.22 £12.99 19% 43% 3883139
NEXIUM CONTROL TABS 20MG 7 £3.58 £7.49 19% 43% 3883147

04/11/2025 16:42:48
P4403.14-V111 December OTC Magazine 2025 NI.indd 33 04/11/2025 16:42:48
P4403.14-V111 December OTC Magazine 2025 NI.indd 33